Brief: Sonnet Biotherapeutics Expect To Be Able To Share Safety Data From Sb102 And Sb221 Studies

Sonnet Biotherapeutics Holdings

14/12/2023 23:26

Dec 14 (Reuters) - Sonnet Biotherapeutics Holdings Inc
 SONN.O :
    * SONNET BIOTHERAPEUTICS HOLDINGS INC: EXPECT TO BE ABLE TO
SHARE
SAFETY DATA FROM SB102 AND SB221 STUDIES OF SON-1010 DURING
FIRST HALF OF YEAR 2024
    * SONNET BIOTHERAPEUTICS HOLDINGS INC: HOPE OF HAVING EARLY
SAFETY
DATA AVAILABLE DURING Q1 OF 2024 FOR PHASE 1B SB211 STUDY OF
SON-080 IN CIPN

Source text for Eikon:  ID: 
Further company coverage:  SONN.O 

 ((Reuters.Briefs@thomsonreuters.com;))